Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Besponsa (inotuzumab ozogamicin) is indicated for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older.
• This summary is based on the review of two systematic reviews/meta-analyses. ^[1-2]
• The complete remission (CR) rate for relapsed/refractory acute lymphoblastic leukemia (ALL) patients treated with inotuzumab ozogamicin (INO) was 67% (95% CI, 61%-73%), with a minimal residual disease (MRD) response rate of 45% (95% CI, 37%-53%).
• In patients with non-Hodgkin lymphoma (NHL) treated with INO, the pooled CR rate was 28% (95% CI, 15%-47%).
• Compared to conventional chemotherapy, CD-targeted immunotherapy for ALL showed higher overall survival (OS) and relapse-free survival (RFS) rates, with pooled odds ratios of 2.11 (95% CI, 1.76-2.53) and 2.25 (95% CI, 1.62-3.14), respectively, alongside improved CR and MRD negativity rates.
• The incidence of hepatic venous obstructive disease/sinus obstructive syndrome in patients receiving inotuzumab ozogamicin (INO) was 8% (95% CI, 5%-14%).
• The incidence of grade ≥3 hematologic adverse events in patients treated with INO included 29% (95% CI, 20%-39%) for thrombocytopenia and 48% (95% CI, 38%-57%) for neutropenia.
• CD-targeted immunotherapy was associated with a lower risk of febrile neutropenia compared to conventional chemotherapy (pooled OR, 0.22; 95% CI, 0.08-0.58).
• There is no population type or subgroup information available in the reviewed studies.